These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26289304)

  • 1. Patient- and therapy-related factors associated with the incidence of xerostomia in nasopharyngeal carcinoma patients receiving parotid-sparing helical tomotherapy.
    Lee TF; Liou MH; Ting HM; Chang L; Lee HY; Wan Leung S; Huang CJ; Chao PJ
    Sci Rep; 2015 Aug; 5():13165. PubMed ID: 26289304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LASSO NTCP predictors for the incidence of xerostomia in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
    Lee TF; Liou MH; Huang YJ; Chao PJ; Ting HM; Lee HY; Fang FM
    Sci Rep; 2014 Aug; 4():6217. PubMed ID: 25163814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Zhao DW; Fan WJ; Fang XM; Luo YR; Wei J; Chen NX; Zhang XX; Liu G; Li JF; Zang X; Li M; Meng L; Ma L
    Radiother Oncol; 2022 Jul; 172():91-98. PubMed ID: 35584742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy.
    Lee TF; Fang FM
    Radiother Oncol; 2013 Mar; 106(3):352-8. PubMed ID: 23333019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parotid gland radiation dose-xerostomia relationships based on actual delivered dose for nasopharyngeal carcinoma.
    Lou J; Huang P; Ma C; Zheng Y; Chen J; Liang Y; Li H; Yin Y; Liu D; Yu G; Li D
    J Appl Clin Med Phys; 2018 May; 19(3):251-260. PubMed ID: 29664218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for improvement of xerostomia in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.
    Pan XB; Liu Y; Huang ST; Chen KH; Jiang YM; Zhu XD
    Medicine (Baltimore); 2019 Sep; 98(36):e17030. PubMed ID: 31490391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy vs segmental multileaf collimator-based techniques.
    Chen AM; Yang CC; Marsano J; Liu T; Purdy JA
    Br J Radiol; 2012 Aug; 85(1016):e537-43. PubMed ID: 22253350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xerostomia in patients treated for oropharyngeal carcinoma: comparing linear accelerator-based intensity-modulated radiation therapy with helical tomotherapy.
    Fortin I; Fortin B; Lambert L; Clavel S; Alizadeh M; Filion EJ; Soulières D; Bélair M; Guertin L; Nguyen-Tan PF
    Head Neck; 2014 Sep; 36(9):1343-8. PubMed ID: 24038408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis.
    Sommat K; Hussain A; Ong WS; Yit NLF; Khoo JBK; Soong YL; Wee JTS; Fong KW; Tan TWK
    Radiother Oncol; 2019 Sep; 138():149-157. PubMed ID: 31265972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion weighted imaging in submandibular gland sparing helical tomotherapy for nasopharyngeal carcinoma.
    Fan WJ; Teng F; Liu G; Zhao DW; Li JF; Luo YR; Zhang XX; Ma L; Guan J
    Radiother Oncol; 2021 Apr; 157():247-254. PubMed ID: 33587972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.
    Huang H; Miao J; Xiao X; Hu J; Zhang G; Peng Y; Lu S; Liang Y; Huang S; Han F; Deng X; Zhao C; Wang L
    Radiother Oncol; 2022 Oct; 175():1-9. PubMed ID: 35817320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy.
    Li M; Zhang J; Zha Y; Li Y; Hu B; Zheng S; Zhou J
    BMC Oral Health; 2022 Jun; 22(1):239. PubMed ID: 35715856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal Evolution of Parotid Volume and Parotid Apparent Diffusion Coefficient in Nasopharyngeal Carcinoma Patients Treated by Intensity-Modulated Radiotherapy Investigated by Magnetic Resonance Imaging: A Pilot Study.
    Juan CJ; Cheng CC; Chiu SC; Jen YM; Liu YJ; Chiu HC; Kao HW; Wang CW; Chung HW; Huang GS; Hsu HH
    PLoS One; 2015; 10(8):e0137073. PubMed ID: 26323091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.